NCT04573777View on ClinicalTrials.gov

Reducing Intracranial atheroSclErosis With Repatha

PHASE4TerminatedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

April 23, 2021

Primary Completion Date

December 16, 2021

Study Completion Date

December 16, 2021

Conditions

Ischemic Stroke

Interventions

DRUG

Repatha

140 MG in 1 ML Prefilled Syringe PCSK9 Inhibitor

Trial Locations (1)

90095

UCLA, Los Angeles

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Amgen

INDUSTRY

lead

University of California, Los Angeles

OTHER

NCT04573777 - Reducing Intracranial atheroSclErosis With Repatha | Biotech Hunter | Biotech Hunter